OnKure Therapeutics Stock Forecast
NASDAQ: OKURHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 10:07 AM ET
OKUR analyst consensus
Consensus (6 analysts)
none
Avg. price target
$15.50+572.45%
- Strong buy 0
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering OnKure Therapeutics (2026-10-09), 5 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $15.50, with a high estimate of $21.00 and a low estimate of $11.00. The average target implies upside of 572.5% from the current price of $2.31.
The spread between the highest and lowest targets is 90.9%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for OKUR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 5 | 83% |
| Hold | 1 | 17% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $11.00 | +377.22% |
| Average target | $15.50 | +572.45% |
| High target | $21.00 | +811.06% |